title: Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Ottaviani
authors.forename: Isabelle
authors.initials: I
authors.lastname: Cerf-Payrastre
authors.forename: Farid
authors.initials: F
authors.lastname: Kemiche
authors.forename: Edouard
authors.initials: E
authors.lastname: Pertuiset
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000175:diagnosis; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000068879:Adalimumab